Table of contents

Extended reports

• Accuracy of quantitative magnetic resonance imaging in the detection of ex vivo focal cartilage defects (7 January, 2005)

  H Graichen, D Al-Shamari, S Hinterwimmer, R von Eisenhart-Rothe, T Vogl, F Eckstein
• Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis (12 July, 2005)

  A Juurikivi, C Sandler, K A Lindstedt, P T Kovanen, T Juutilainen, M J Leskinen, T Mäki, K K Eklund
• Treatment of experimental arthritis with poly(d, l-lactic/glycolic acid) nanoparticles encapsulating betamethasone sodium phosphate

  (4 February, 2005)

  M Higaki, T Ishihara, N Izumo, M Takatsu, Y Mizushima
• Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment (7 January, 2005)

  K Briot, P Garnero, A Le Henanff, M Dougados, C Roux
• Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T₁ and short tau inversion recovery (STIR) sequences

  (13 January, 2005)

  X Baraliakos, K-G A Hermann, R Landewé, J Listing, W Golder, J Brandt, M Rudwaleit, M Bollow, J Sieper, D van der Heijde, J Braun
• Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis (4 February, 2005)

  B Vander Cruyssen, I E A Hoffman, H Zmierczak, M Van den Berghe, E Kruithof, L De Rycke, H Mielants, E M Veys, D Baeten, F De Keyser
• Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (27 January, 2005)

  C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh
• Level of acceptability of EULAR recommendations for the management of knee osteoarthritis by practitioners in different European countries (11 February, 2005)

  B Mazières, N Scmidely, H J Hauselmann, E Martin-Mola, U Serni, A A Verbruggen, M Le Bars
• Up regulated expression of tumour necrosis factor α converting enzyme in peripheral monocytes of patients with early systemic sclerosis (12 July, 2005)

  T Bohgaki, Y Amasaki, N Nishimura, M Bohgaki, Y Yamashita, M Nishio, K-i Sawada, S Jodo, T Atsumi, T Koike
• Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial (11 February, 2005)

  G Kobelt, P Lindgren, A Singh, L Klareskog
• Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study (27 January, 2005)

  T Dervieux, D Furst, D O Lein, R Capps, K Smith, J Caldwell, J Kremer
• Response criteria for rheumatoid arthritis in clinical practice: how useful are they? (10 March, 2005)

  A Gülfe, P Geborek, T Saxne
• Association of polymorphism in the transforming growth factor β1 gene with disease outcome and mortality in rheumatoid arthritis (4 February, 2005)

  D L Mattey, N Nixon, P T Dawes, J Kerr
• Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis (24 February, 2005)

  C Popa, M G Netea, T R D S Radstake, P L van Riel, P Barrera, J W M van der Meer
• Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis (7 January, 2005)

  M M J Nielen, A R van der Horst, D van Schaardenburg, I E van der Horst-Bruinsma, R J van de Stadt, L Aarden, B A C Dijkmans, D Hamann
• Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome (11 February, 2005)

  R Cervera, J Font, J A Gómez-Puerta, G Espinosa, M Cucho, S Bucciarelli, M Ramos-Casals, M Ingelmo, J-C Piette, Y Shoenfeld, R A Asherson
• Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus (11 February, 2005)

  E S Husebye, Z M Sthoeger, M Dayan, H Zinger, D Elbirt, M Levite, E Mozes